NEW YORK (GenomeWeb News) – Swiss biochemical extraction company Spinomix has closed a Series A equity investment of $3 million, with the funds coming from existing and new investors, the company said today.

The round of financing was led by Debiopharm Group, a collection of biopharmaceutical companies focused on drug development and investing in startups, primarily in the molecular diagnostics and personalized medicine fields. The funding also included support from previous investors and a private, undisclosed US-based investor group.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Marcia McNutt, the editor-in-chief of Science, has been nominated to become president of the US National Academy of Sciences.

In PNAS this week: human cytomegalovirus diversity, patterns of homologous recombination in E. coli, and more.

US lawmakers are considering eliminating the medical devices tax that is part of the Affordable Care Act.

Two research teams in China home in on a gene that gives rice a long, slender shape.

Jul
14
Sponsored by
Agilent Technologies

This online seminar will outline a recent example of the use of molecular barcoding in combination with next-generation sequencing to detect somatic mosaicism in cancer patients.